Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be
Novartis sent out a loud and clear message this morning: Despite folding its standalone cell therapy unit, the pharma giant says it remains on track to deliver an application for its CAR-T CTL-019 for pediatric acute lymphoblastic leukemia “in early 2017.” And an application for diffuse large B cell lymphoma is due in the second half of next year, which could put it well behind rival Kite Pharma. At the same time, the pharma giant — now under assault from generic competition — boasted about a dozen late-stage programs with blockbuster potential to earn more than a billion dollars a year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.